CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong

Revenues amounted to $28.6 million, which went down from $66.8 million in the year-ago quarter but surpassed the Zacks Consensus Estimate of $20 million.

Cytokinetics’ shares have surged 28.1% year to date compared with the industry’s 3.6% growth.

Image Source: Zacks Investment Research

CYTK’s Myqorzo Launch Gains Momentum

In December 2025, the FDA approved Myqorzo (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

Net product revenues from Myqorzo were $25.3 million in the second quarter. U.S. net product revenues totaled $23.0 million, while Europe contributed $2.30 million, reflecting initial distributor inventory purchases in Germany.

Commercial adoption continued to broaden. More than 700 unique U.S. healthcare providers prescribed Myqorzo by June 30. More than 80% of dispensed prescriptions were paid, and management’s internal analysis indicated Myqorzo exited the quarter with greater than 40% new-to-brand prescription share in the cardiac myosin inhibitor category.

Cytokinetics launched Myqorzo in Germany in June, marking its first European commercial rollout. The drug also received marketing authorization across the United Kingdom, while NICE recommended it for use in England and Wales.

CYTK’s Revenue Mix Shifts From Milestones

Beyond product sales, quarterly revenues included collaboration revenues of $3.29 million, up from $2.42 million in the year-ago quarter. No license and milestone revenues were recorded in the period.

That absence caused the sharp year-over-year decline in total revenues. The second quarter of 2025 included $64.35 million in license and milestone revenues tied to the Bayer BAYRY collaboration for aficamten in Japan.

Cytokinetics Sees Higher Commercial Spending

Research and development expenses declined 11.2% year over year to $97.81 million. The decrease reflected higher clinical trial activity, supply-chain costs and medical affairs spending in the prior-year period, partly offset by higher personnel-related costs in 2026.

Selling, general and administrative expenses rose 58.8% to $104.40 million. The increase reflected Myqorzo launch costs, the U.S. sales force and higher nonsales personnel-related expenses, including stock-based compensation.

CYTK Ends Q2 With a Stronger Cash Position

Cash, cash equivalents and investments totaled approximately $1.7 billion as of June 30, 2026, compared with $1.1 billion at the end of the first quarter.

The increase primarily reflected a May public offering that generated approximately $760.1 million in net proceeds. The additional liquidity provides Cytokinetics with the financial flexibility to support the commercialization of Myqorzo and continue investing across its specialty cardiology pipeline.

CYTK Raises 2026 Expense Guidance

Cytokinetics now expects combined 2026 GAAP R&D and SG&A expenses of $860-$890 million, up from its prior projection of $830-$870 million. The company also raised its stock-based compensation expense guidance to $130-$140 million from $120-$130 million.

Excluding stock-based compensation, combined R&D and SG&A expenses are projected to be in the $720-$760 million band. Management tied the increase primarily to commercial-readiness investments following positive ACACIA-HCM results and preparations for a potential 2027 Myqorzo launch in non-obstructive hypertrophic cardiomyopathy (nHCM).

CYTK’s Updates on Aficamten

On the clinical front, ACACIA-HCM met both primary endpoints in symptomatic nHCM, showing statistically significant improvements in KCCQ Clinical Summary Score and peak VO2 versus placebo. Cytokinetics plans to submit a supplemental new drug application (sNDA) for aficamten in this indication in the fourth quarter of 2026.

The FDA accepted CYTK’s sNDA for MAPLE-HCM, a phase III study of aficamten as monotherapy compared with metoprolol as monotherapy in patients with oHCM. The regulatory body assigned a target action date of Nov. 14, 2026.

The company has also submitted new drug applications for aficamten in Hong Kong and Taiwan under its collaboration with Sanofi. Aficamten has been granted Priority Review designation by the Taiwan Food and Drug Administration. Meanwhile, regulatory filings for Myqorzo are also under review in Canada and Switzerland.

The clinical development of aficamten, including the ongoing Japan cohort of the ACACIA-HCM study, is advancing. The company expects to complete the study in the third quarter of 2026.

CAMELLIA-HCM, a phase III study of aficamten in Japanese patients with oHCM, is also ongoing. The study is being conducted by Bayer in collaboration with Cytokinetics to support potential marketing authorization in Japan.

Other studies include CEDAR-HCM, a clinical trial of aficamten in a pediatric population with symptomatic oHCM. The study recently completed patient enrollment in the adolescent cohort of the study.

Cytokinetics’ Other Pipeline Candidates

Other pipeline candidates include omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. A confirmatory phase III multi-center, double-blind, randomized, placebo-controlled trial, COMET-HF, to assess the efficacy and safety of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction is ongoing. Enrollment is expected to continue through 2026.

The company continued enrolling patients in cohort 1 of the phase II AMBER-HFpEF trial evaluating ulacamten in patients with symptomatic heart failure with preserved ejection fraction and a left ventricular ejection fraction of at least 60%. Patient enrollment is expected to be completed in the Cohort 1 in the second half of 2026.

The company recently initiated the second phase I randomized, double-blind, placebo-controlled, single ascending dose study of CK-4015089 (CK-089) in healthy volunteers.

Our Take on CYTK’s Performance

CYTK performance in the second quarter was encouraging.

Myqorzo’s uptake is a strong early signal. The oHCM market represents a meaningful commercial opportunity, given the sizable population of symptomatic patients who have historically had limited pharmacologic options beyond beta-blockers, calcium channel blockers, or invasive procedures. The approval positions Cytokinetics as a key player in this growing specialty cardiology segment.

A potential approval in nHCM will expand the addressable market.

However, Myqorzo faces competition from Camzyos (mavacamten), a first-in-class cardiac myosin inhibitor marketed by Bristol Myers Squibb BMY.

BMY obtained FDA approval for the drug in 2022 for the treatment of adults with symptomatic New York Heart Association class II-III obstructive HCM to improve functional capacity and symptoms.

Camzyos has put up a stellar performance since its approval.

CYTK’s Zacks Rank & Key Picks

Cytokinetics currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research